ERBB2 and breast cancer: Here, we analyzed data from plasma samples prospectively collected from HER2-positive BC patients receiving trastuzumab-based NAT within the NeoALTTO trial [16] to identify changes in ct-miRNAs levels during the first two weeks of treatment, and to explore any association of early ct-miRNA dynamics with final patient response to NAT and clinical outcome.